Skip to main content
Clinical Trials/NCT02291224
NCT02291224
Completed
N/A

Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens

Centers for Disease Control and Prevention1 site in 1 country709 target enrollmentMarch 2015

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pregnancy
Sponsor
Centers for Disease Control and Prevention
Enrollment
709
Locations
1
Primary Endpoint
Incidence of pregnancy and sexually transmitted infections (STIs)
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This trial will evaluate a multi-component, clinic-based intervention aimed at increasing dual protection strategy selection and adherence among young African American females at an urban family planning clinic. Dual protection is the use of contraceptive strategies to prevent both unintended pregnancy (UIP) and sexually transmitted infections (STIs). This is an unblinded randomized controlled trial; participants will either get the interactive multimedia platform focused on DP strategies with intervention arm counseling or the standard of care arm counseling.

The study will recruit 710 African American females aged 14-19 who are attending the Grady Health System (GHS) Teen Services Clinic (TSC) in Atlanta, Georgia, for reproductive health care.

The trial will recruit and enroll 710 young women presenting to the clinic for clinical care who have the following characteristics:

  • self-identify as African American,
  • 14-19 years of age,
  • have had vaginal sex with a male partner in the past 6 months,
  • HIV-negative by self-report,
  • not pregnant,verified by urine pregnancy test,
  • no desire to be pregnant in next 12 months,
  • plan to stay in the Atlanta area for the next year,
  • are willing to provide contact information, and
  • were not previously enrolled in the pilot study of this intervention.

Those enrolled will be in the study for 12 months. Young women who are eligible and give written consent or assent for study participation will be enrolled. Half will be randomized to the control arm, half to the intervention arm.

  1. Control arm (standard of care) includes individual clinical care and standard of care counseling consistent with protocols at the TSC, with study visits for data collection at enrollment, 6 months, and 12 months, during which any medical care or counseling that they would normally get will also be provided. Control arm participants will also get telephone calls from clinic staff to update their contact information and remind them of upcoming visits at 3 weeks and 5 months after the enrollment visit, and at 3 weeks and 5 months after the 6 month visit.

  2. Intervention arm, consisting of the following intervention components:

    1. Enrollment visit

      • A culturally-appropriate interactive multimedia platform focused on DP strategies and designed to prepare the individual for selection of a DP strategy.
      • Individual intervention arm counseling to select the DP strategy that is best suited for the participant (by a clinic health care provider).
      • Individual intervention arm counseling to build skills for correct and consistent use of the selected DP strategy (by a nurse educator (NE)).
    2. Booster counseling via phone at about 3 weeks and 5 months after the enrollment visit, and at about 3 weeks and 5 months after the 6 month visit (by an NE).

    3. 6 month visit

      • An abbreviated version of the interactive multimedia platform focused on dual protection strategies and strategy adherence.
      • Individual intervention arm counseling to reinforce skills for correct and consistent use of the DP strategy (by an NE).

At the final study visit at 12 months there is no difference between the counseling provided to the two groups; participants in both arms will receive the clinic standard of care.

Participants in both arms of the study will follow the same data collection procedures throughout the study:

  • At all three study visits, participants in both arms will receive urine pregnancy and STI tests and complete an audio computer assisted self-interview (ACASI) questionnaire.
  • At 3 and 9 months after enrollment, participants in both arms will receive a data collection call with administration of a telephone questionnaire.

Throughout the study, all participants will be encouraged to come in for evaluation if they have any concerns. Any data from pregnancy or STI testing at these interim clinic visits will be later collected via chart review. If participants seek reproductive health care at other facilities during the study period, records will be requested with participant permission, and data from pregnancy or STI testing at these outside clinic visits will be collected via review of records received.

We will examine the efficacy of the intervention arm relative to control arm across the following primary behavioral and biologic outcomes over the 12 months of follow-up:

  1. Self-reported dual protection strategy selection
  2. Self-reported dual protection strategy adherence
  3. Incidence of pregnancy or infection with chlamydia, gonorrhea or trichomonas (as confirmed by laboratory testing)

A small pilot study was be conducted prior to the initiation of enrollment in the main study.

Registry
clinicaltrials.gov
Start Date
March 2015
End Date
August 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • self-identify as African American,
  • 14-19 years of age,
  • present to clinic on date of potential enrollment for clinical care,
  • has had vaginal sex with a male partner at least once in the past 6 months,
  • HIV-negative by self-report,
  • not currently pregnant (verified by urine pregnancy test),
  • desire to avoid pregnancy for at least 12 months,
  • plan to be in the Atlanta area for the next 12 months,
  • competent to participate in consenting or assenting process per recruiter evaluation,
  • willing to provide contact information, and

Exclusion Criteria

  • HIV positive

Outcomes

Primary Outcomes

Incidence of pregnancy and sexually transmitted infections (STIs)

Time Frame: Within 12 month period following enrollment

Includes the proportion of participants with a lab-confirmed diagnosis of pregnancy or lab-confirmed diagnosis with infection with chlamydia, gonorrhea or trichomonas within the 12 month follow-up period (testing either performed at study site clinic and documented at study visits and via chart review, or diagnosed by outside labs with documentation obtained via release of information procedures)

Participant selection of an effective dual protection (DP) strategy

Time Frame: At enrollment visit

Whether or not a participant self-reports having selected an effective DP strategy. An effective DP strategy is defined as one of the following: * Abstinence from vaginal sex; * Effective non-barrier contraceptive method \[including intrauterine device (IUD), Implant, Depo, or contraceptive pill, patch or ring\] with consistent condom use; * Consistent condom use only

Time to first biologic event (pregnancy or diagnosis with STI) in participants

Time Frame: Within 12 month period following enrollment

Measured by date of positive lab test ("biologic event" refers to a positive pregnancy test or diagnosis with chlamydia, gonorrhea or trichomonas infection).

Participant report of adherence to DP strategy

Time Frame: 12 months

By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes: * Whether or not DP strategy was used at last sex * Whether or not DP strategy was used consistently during last 3 month time period * Estimated proportion of time adherent to DP strategy over last 3 months

Secondary Outcomes

  • Participant level of reproductive health knowledge (percentage correct of knowledge questions)(12 months)
  • Participant report of partner communication(12 months)
  • Participant reproductive health self-efficacy(12 months)
  • Participant report of STI testing(12 months)
  • Participant intention to use DP strategy(12 months)

Study Sites (1)

Loading locations...

Similar Trials